{
  "authors": [
    {
      "author": "Nobuhisa Matsuhashi"
    },
    {
      "author": "Takao Takahashi"
    },
    {
      "author": "Kenichi Nonaka"
    },
    {
      "author": "Kengo Ichikawa"
    },
    {
      "author": "Kazunori Yawata"
    },
    {
      "author": "Toshiyuki Tanahashi"
    },
    {
      "author": "Hisashi Imai"
    },
    {
      "author": "Yoshiyuki Sasaki"
    },
    {
      "author": "Yoshihiro Tanaka"
    },
    {
      "author": "Naoki Okumura"
    },
    {
      "author": "Kazuya Yamaguchi"
    },
    {
      "author": "Shinji Osada"
    },
    {
      "author": "Kazuhiro Yoshida"
    }
  ],
  "doi": "10.1186/1477-7819-12-35",
  "publication_date": "2014-02-13",
  "id": "EN116124",
  "url": "https://pubmed.ncbi.nlm.nih.gov/24517087",
  "source": "World journal of surgical oncology",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "A 73-year-old male with sigmoid colon cancer and synchronous lung metastasis was treated with panitumumab, an alone anti-EGFR monoclonal antibody as the third-line therapy.During the nine courses of the therapy, the response was stable disease (SD), but skin disorder gradually appeared obviously (CTCAE version 4.0: Grade 2). After 1 month of administration of Aboundâ„¢, symptoms of the skin disorder improved (CTCAE version 4.0: Grade 1), thus the antibody therapy could be continued."
}